or Login to see your representatives.

Access Candidates' and Representatives' Biographies, Voting Records, Interest Group Ratings, Issue Positions, Public Statements, and Campaign Finances

Simply enter your zip code above to get to all of your candidates and representatives, or enter a name. Then, just click on the person you are interested in, and you can navigate to the categories of information we track for them.

Public Statements

Food and Drug Administration Safety and Innovation Act

Floor Speech

By:
Date:
Location: Washington, DC

BREAK IN TRANSCRIPT

Mr. GINGREY of Georgia. Mr. Speaker, I thank the gentleman for yielding.

The FDA Safety and Innovation Act of 2012 may not be a great bill, but it is a darn good bill. And as a physician and a member of the Energy and Commerce Committee, I strongly support it.

As my colleagues have said on both sides, this is a bicameral, bipartisan piece of legislation, and yes, we can get our work done. I want to particularly thank Chairman Upton, Ranking Member Waxman, Health Subcommittee Chairman Pitts, Ranking Member Pallone, and all of the Members that have worked so hard on this really vast, huge bill that covers a lot of things, not the least of which, of course, is to provide 65 percent of the funding for the FDA so they can, indeed, hire the best and brightest scientists so they get their work done in a timely manner, get new drugs to the market, medical devices, and bottom line, keep the health care system in this country the best in the world for our constituents and our patients.

Mr. Speaker, I want to mention one particular aspect of the bill that I was very much involved in, and that's this issue of antibiotic shortage. The bill as it stood alone was called the GAIN Act, and I had a tremendous amount of help on both sides of the aisle. On the Democratic side, there was Congresswoman Eshoo, Congresswoman DeGette, and Congressman Gene Green. On my side of the aisle, there was Mike Rogers of Michigan, Mr. Shimkus, and Mr. Whitfield. What we do with that portion of the bill is to provide an opportunity for the manufacturers of antibiotics to have an additional 5 years of exclusivity so they can bring these innovative fifth- and sixth-generation antibiotics to the market and still have an opportunity to recoup the investment and the expense of doing so.

I want to just say to my colleagues on both sides of the aisle, it's a proud day, I think, for all of us, for Chairman Emeritus Dingell, the former chairman on our side of the aisle, Mr. Barton, and everybody involved in this bill. I thank all of you. Let's all unanimously support this bill.

BREAK IN TRANSCRIPT


Source:
Back to top